Long-Acting Cabenuva Shows Sustained Virologic Suppression in Urban Communities

Originally published by our sister publication Infectious Disease Special EditionBy Ethan CoveyA real-world evaluation of long-acting cabotegravir-rilpivirine (Cabenuva, ViiV Healthcare) within two ambulatory care clinics in New Jersey found that patients consistently maintained virologic suppression after switching from oral antiretroviral therapy, supporting the regimen’s effectiveness as ART outside controlled clinical trial settings.figure img { width:100% !important; } figcaption { pa